Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss,…
Bring Your Toughest AM Quality Problem To Formnext: Amsight Challenges Manufacturers To Rethink Production Quality
Mentionkit Publishes SourcetoMCP Case Study on Social Listening for B2B SaaS